期刊文献+

帕金森患者手术前应用氯胺酮的治疗作用

原文传递
导出
摘要 黑质多巴胺神经元的减少是帕金森病的典型病理特征,但持续性N-甲基-D-天门冬氨酸受体激活也是一个重要的组成部分。1例进展期帕金森病患者在处理困难气道过程中,静注小剂量氯胺酮(20mg)完全缓解了震颤和发音障碍。这促使了本项病例报道,应用小剂量氯胺酮进行手术前镇静并缓解运动障碍。既往研究和我们的经验均建议根据其效用可给予小剂量氯胺酮,使患者更为舒适,并有利于控制围手术期的帕金森震颤。 Loss of dopaminergic neurons from the substantia nigra characterizes the dassical pathology of Parkinson's disease, but persistent activation of N-methyl-D-aspartate receptors is also a major component. During difficult airway man- agement in a patient with advanced Parkinson's disease, the use of low-dose (20 nag) IV ketamine resulted in complete abolition of severe tremor and dysarthria. This led to the current case report in which low-dose ketamine was used for preoperative sedation and dyskinesia attenuation. Prior research and our experience would suggest that low-dose ketamine, titrated to effect, may provide optimal patient comfort and perioperative control of Parkinsonian tremor.
出处 《麻醉与镇痛》 2010年第2期87-89,共3页 Anesthesia & Analgesia
  • 相关文献

参考文献12

  • 1Hallett PJ, Standaert DG. Rationale for and use of NMDA receptor antagonists in Parkinson's disease. Pharmacol Ther 2004,102:155-74. 被引量:1
  • 2Nicholson G, Pereira AC, Hall GM. Parkinson's disease and anaesthesia. Br JAnaesth 2002:89:904-16. 被引量:1
  • 3Starr MS, Starr BS, Kaur S. Stimulation of basal and L-DOPA induced motor activity by glutamate antagonists in animal models of Parkinson's disease. Neurosci Biobehav Rev 1997;21: 437-46. 被引量:1
  • 4Lang AE, Lozano AM. Parkinson's disease: first of two parts. N Engl J Med 1998:339:1044-53. 被引量:1
  • 5Whitton PS. Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol 2007:150:963-76. 被引量:1
  • 6Vincken WG, Gauthier SG, Dollfuss RE, Hanson RE, Darauay CM, Cosio MG. Involvement of upper-airway muscles in extra- pyramidal disorders. A cause of airflow limitation. N Engl J Med 1984:311:438-42. 被引量:1
  • 7Neu HC, Connolly JJ Jr. Schwertley FW, Ladwig HA, Brody AW. Obstructive respiratory dysfunction in parkinsonian patients. Am Rev Respir Dis 1967,95:33-47. 被引量:1
  • 8Wu S, Frucht S. Treatment of Parkinson's Disease-What's on the Horizon? CNS Drugs 2005:19:723-43. 被引量:1
  • 9Snow B, Macdonald L. Mcauley D, Wallis W. The effect of amantadine on levodopa-induced dyskinesias in parkinson's disease: a double-blind, placebo-controlled study. Clin Neuropharmacol 2000;23:82-5. 被引量:1
  • 10Silva-Junior F, Braga-Neto P. Monte F, Sales de Bruin V. Amantadine reduces the duration of levodopa-induced dyskinesia: A randomized, double-blind, placebo-controlled study. Parkinsonism Relat Disord 2005;11:449-52. 被引量:1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部